Trial Profile
Switching to aflibercept in patients with neovascular AMD not responding to anti-VEGF treatment. [Overstappen op aflibercept in patiënten die niet reageren op anti-VEGF therapie.]
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Bayer
- 15 Mar 2021 Status changed from recruiting to completed.
- 20 Nov 2013 New trial record